Peter Enzinger

Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

Lauren L. Ritterhouse, J. Meyerhardt, D. Rubinson, 2024, Nature communications.

Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting

Harshabad Singh, Z. Sztupinszki, S. Spisák, 2024, NPJ precision oncology.